贝瑞基因(000710) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥279,476,530.07, a decrease of 0.26% compared to ¥280,207,812.40 in the same period last year[5] - Net profit attributable to shareholders was ¥8,235,122.95, representing a significant increase of 139.71% from a loss of ¥20,738,437.15 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥9,989,880.84, up 148.79% from a loss of ¥20,476,612.23 year-on-year[5] - Basic and diluted earnings per share improved to ¥0.02, compared to a loss of ¥0.06 in the same period last year, marking a 133.33% increase[5] - Total operating revenue for Q1 2024 was CNY 279,476,530.07, a slight decrease from CNY 280,207,812.40 in the previous period[19] - Net profit for Q1 2024 was CNY 9,419,004.86, a significant recovery from a net loss of CNY 20,110,444.46 in the same period last year[20] - The total comprehensive income for Q1 2024 was ¥9,482,565.46, compared to a loss of ¥22,543,430.36 in the previous year[21] - The company’s total comprehensive income attributable to the parent company was ¥8,286,546.07, compared to a loss of ¥22,583,135.87 in the previous year[21] Asset Management - The company's total assets at the end of Q1 2024 were ¥2,699,257,673.02, a decrease of 1.53% from ¥2,741,165,147.34 at the end of the previous year[5] - Cash and cash equivalents decreased from RMB 338.15 million to RMB 246.68 million, a decline of approximately 27%[15] - Accounts receivable increased from RMB 807.95 million to RMB 888.59 million, reflecting a growth of about 9.9%[15] - The total assets decreased to CNY 2,699,257,673.02 from CNY 2,741,165,147.34, indicating a reduction in asset base[17] - Current liabilities decreased to CNY 713,030,608.35 from CNY 763,091,802.49, showing improved liquidity management[17] - The equity attributable to shareholders increased to CNY 1,872,321,592.86 from CNY 1,864,035,046.79, indicating a strengthening of the company's financial position[17] Cash Flow - The net cash flow from operating activities was -¥42,721,485.35, slightly worse than -¥41,528,166.03 in the previous year, a decrease of 2.87%[5] - The net cash flow from investing activities was -¥7,809,905.81, a decline from a positive cash flow of ¥4,482,626.74 in the previous year[24] - The company incurred cash outflows of ¥280,376,803.09 from operating activities, compared to ¥337,608,941.20 in the previous year[24] - The company reported a total cash inflow from operating activities of ¥237,655,317.74, down from ¥296,080,775.17 in the previous year[23] - Cash and cash equivalents at the end of the period totaled ¥246,677,815.54, down from ¥287,762,453.40 at the end of the previous year[24] - The company raised ¥10,000,000.00 from financing activities, a decrease from ¥27,763,462.67 in the previous year[24] Investment and Development - The company reported a significant reduction in investment losses, with losses decreasing by 70.29% to -¥2,803,568.59 from -¥9,436,348.18 year-on-year[9] - The company experienced a 39.71% increase in tax payments, totaling ¥22,591,364.84, compared to ¥16,170,026.56 in the previous year[9] - The cash outflow for the acquisition of fixed assets increased by 290.31% to ¥7,811,585.81 from ¥2,001,375.48 in the same period last year[9] - The company has decided to pause the construction of the Fujian Industrial Park and seek external partners for joint development and operation[13] - A joint venture has been established with Fuzhou Lintong Construction, with a total investment of RMB 350 million, where Fuzhou Lintong contributes RMB 178.5 million (51%) and Chengdu Beirui contributes RMB 171.5 million (49%)[13] - The acquisition price for the rights to the Fujian Industrial Park is RMB 501.83 million[13] - The company has a total of 99,573 square meters of land use rights for the Fujian Industrial Park[13] Operational Strategy - The company is focusing on its core business and tightening operational strategies[13] - The company plans to continue focusing on market expansion and new product development as part of its growth strategy[20] - Research and development expenses remained stable at CNY 20,699,969.47, reflecting ongoing investment in innovation[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 57,561[12] - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.45% of shares, totaling 44,002,000 shares[12] - The company has not reported any changes in the participation of major shareholders in margin trading[14] Cost Management - Total operating costs decreased to CNY 247,333,978.52 from CNY 282,899,819.60, indicating improved cost management[19] - The company reported a gross profit margin of approximately 11.4% for Q1 2024, compared to a negative margin in the previous year[20] - The weighted average return on equity was 0.44%, an increase of 1.35% compared to -0.91% in the same period last year[5]